ASX-listed biotech PharmAust, has successfully reformulated its promising anti-cancer drug “Monepantel”. Perth-based PharmAust says the new form of Monepantel, which now takes the form of dry tablets, improves the drug’s taste and meets dosage requirements, paving the way for trials in dogs expected to take place by the end of the year ahead of human clinical trials.
28/05/2018 - 22:26
PharmAust successfully reformulates cancer drug
By Matt Birney
28/05/2018 - 22:26
Related Data & Insights
-
-
Rank Company Revenue th PharmAust $842k 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX